The FORTE trial (NCT02203643) aimed to compare responses to carfilzomib when combined with lenalidomide-dexamethasone (KRd) or with cyclophosphamide-dexamethasone (KCd) for newly diagnosed multiple myeloma (MM). Francesca Gay, MD, from the Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy, discusses the results presented from this study at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. While both therapies were effective and well tolerated, KRd treatment yielded better overall responses, in addition to improved rates of MRD negativity, in both high- and low-risk patients.
FORTE: effective treatment of newly diagnosed MM with KRd
